Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition

Kidney International

Volumn 89, Issue 2, 2016, Pages 374-385

  Katagiri, Daisuke ^a   Hamasaki, Yoshifumi ^a   Doi, Kent ^a   Negishi, Kousuke ^a   Sugaya, Takeshi ^b   Nangaku, Masaomi ^a   Noiri, Eisei ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Strategic and Regulatory Affairs Consulting Department   (Japan)

Author keywords

acute kidney injury; chronic kidney disease; fibrosis; oxidative stress

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); BIOLOGICAL MARKER; CISPLATIN; CREATININE; FATTY ACID BINDING PROTEIN; L TYPE FATTY ACID BINDING PROTEIN; NITROGEN; PXS 4728A; SEMICARBAZIDE; UNCLASSIFIED DRUG; UREA; ACTIN; ALLYLAMINE; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; AMINE OXIDASE (COPPER CONTAINING); ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CCL2 PROTEIN, MOUSE; FABP1 PROTEIN, HUMAN; INTERLEUKIN 6; INTERLEUKIN-6, MOUSE; MONOCYTE CHEMOTACTIC PROTEIN 1; PXS-4728A; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VASCULOTROPIN A;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ACTIVITY; DRUG EFFECT; ENZYME INHIBITION; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; KIDNEY TUBULE NECROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; TRANSGENIC MOUSE; UREA NITROGEN BLOOD LEVEL; URINALYSIS; ACUTE KIDNEY INJURY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; FIBROSIS; GENETICS; KIDNEY; METABOLISM; PATHOLOGY; PRECLINICAL STUDY;

ACTINS; ACUTE KIDNEY INJURY; ALLYLAMINE; AMINE OXIDASE (COPPER-CONTAINING); ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHEMOKINE CCL2; CISPLATIN; DRUG EVALUATION, PRECLINICAL; FATTY ACID-BINDING PROTEINS; FIBROSIS; INTERLEUKIN-6; KIDNEY; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84946131285     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.327     Document Type: Article

References (93)

1. S.G. Coca, S. Singanamala, and C.R. Parikh Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis Kidney Int 81 2012 442 448
2. KDIGO Clinical practice guideline for acute kidney injury Kidney Int Supplements 2 2012 1 124
3. C.V. Thakar, A. Christianson, J. Himmelfarb, and et al. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus Clin J Am Soc Nephrol 6 2011 2567 2572
4. I.D. Bucaloiu, H.L. Kirchner, E.R. Norfolk, and et al. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury Kidney Int 81 2012 477 485
5. G.P. Kaushal, and S.V. Shah Challenges and advances in the treatment of AKI J Am Soc Nephrol 25 2014 877 883
6. A.J. Lewington, J. Cerda, and R.L. Mehta Raising awareness of acute kidney injury: a global perspective of a silent killer Kidney Int 84 2013 457 467
7. C. Langenberg, S.M. Bagshaw, C.N. May, and et al. The histopathology of septic acute kidney injury: a systematic review Crit Care 12 2008 R38
8. K. Doi, A. Leelahavanichkul, P.S. Yuen, and et al. Animal models of sepsis and sepsis-induced kidney injury J Clin Invest 119 2009 2868 2878
9. Q. Wei, and Z. Dong Mouse model of ischemic acute kidney injury: technical notes and tricks Am J Physiol Renal Physiol 303 2012 F1487 F1494
10. L.S. Chawla, and P.L. Kimmel Acute kidney injury and chronic kidney disease: an integrated clinical syndrome Kidney Int 82 2012 516 524
11. E.P. Bottinger, and M. Bitzer TGF-beta signaling in renal disease J Am Soc Nephrol 13 2002 2600 2610
12. D.A. Ferenbach, and J.V. Bonventre Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD Nat Rev Nephrol 11 2015 264 276
13. M. Nangaku Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure J Am Soc Nephrol 17 2006 17 25
14. B. Kaissling, M. Lehir, and W. Kriz Renal epithelial injury and fibrosis Biochim Biophys Acta 1832 2013 931 939
15. X.M. Meng, D.J. Nikolic-Paterson, and H.Y. Lan Inflammatory processes in renal fibrosis Nat Rev Nephrol 10 2014 493 503
16. L.S. Chawla, P.W. Eggers, R.A. Star, and et al. Acute kidney injury and chronic kidney disease as interconnected syndromes N Engl J Med 371 2014 58 66
17. A.Q. Lam, and B.D. Humphreys Onco-nephrology: AKI in the cancer patient Clin J Am Soc Nephrol 7 2012 1692 1700
18. Z.H. Siddik Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 2003 7265 7279
19. M.A. Perazella Onco-nephrology: renal toxicities of chemotherapeutic agents Clin J Am Soc Nephrol 7 2012 1713 1721
20. N. Pabla, and Z. Dong Cisplatin nephrotoxicity: mechanisms and renoprotective strategies Kidney Int 73 2008 994 1007
21. D. Katagiri, Y. Hamasaki, K. Doi, and et al. Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection J Am Soc Nephrol 24 2013 2034 2043
22. D.C. Dobyan Long-term consequences of cis-platinum-induced renal injury: a structural and functional study Anat Rec 212 1985 239 245
23. T. Iguchi, M. Nishikawa, B. Chang, and et al. Edaravone inhibits acute renal injury and cyst formation in cisplatin-treated rat kidney Free Radic Res 38 2004 333 341
24. K. Doi, K. Negishi, T. Ishizu, and et al. Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit Crit Care Med 39 2011 2464 2469
25. D. Katagiri, K. Doi, K. Honda, and et al. Combination of two urinary biomarkers predicts acute kidney injury after adult cardiac surgery Ann Thorac Surg 93 2012 577 583
26. K. Doi, D. Katagiri, K. Negishi, and et al. Mild elevation of urinary biomarkers in prerenal acute kidney injury Kidney Int 82 2012 1114 1120
27. A. Kamijo, T. Sugaya, A. Hikawa, and et al. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial J Lab Clin Med 145 2005 125 133
28. A. Kamijo, T. Sugaya, A. Hikawa, and et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease Mol Cell Biochem 284 2006 175 182
29. J.S. Foot, M. Deodhar, C.I. Turner, and et al. The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) Bioorg Med Chem Lett 22 2012 3935 3940
30. K. Koskinen, P.J. Vainio, D.J. Smith, and et al. Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1) Blood 103 2004 3388 3395
31. G. Esteban, I. Bolea, P. Sun, and et al. A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE J Neural Transm 120 2013 911 918
32. T. Tabi, E. Szoko, A. Merey, and et al. Study on SSAO enzyme activity and antiinflammatory effect of SSAO inhibitors in animal model of inflammation J Neural Transm 120 2013 963 967
33. F. Ishizaki Plasma benzylamine oxidase activity in cerebrovascular disease Eur Neurol 30 1990 104 107
34. F. Boomsma, F.H. Derkx, A.H. van den Meiracker, and et al. Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated haemoglobin Clin Sci 88 1995 675 679
35. F. Boomsma, D.J. van Veldhuisen, P.J. de Kam, and et al. Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure Cardiovasc Res 33 1997 387 391
36. J. O'Sullivan, M. Unzeta, J. Healy, and et al. Semicarbazide-sensitive amine oxidases: enzymes with quite a lot to do Neurotoxicology 25 2004 303 315
37. M.Y. Wong, S. Saad, C. Pollock, and et al. Semicarbazide-sensitive amine oxidase and kidney disease Am J Physiol Renal Physiol 305 2013 F1637 F1644
38. M. Wong, S. Saad, J. Zhang, and et al. Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model Am J Physiol Renal Physiol 307 2014 F908 F916
39. K. Doi, E. Noiri, and T. Sugaya Urinary L-type fatty acid-binding protein as a new renal biomarker in critical care Curr Opin Crit Care 16 2010 545 549
40. P.A. McCullough, A.D. Shaw, M. Haase, and et al. Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference Contrib Nephrol 182 2013 13 29
41. K. Doi, Y. Suzuki, A. Nakao, and et al. Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney Kidney Int 65 2004 1714 1723
42. H. Fujita, T. Morii, H. Fujishima, and et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential Kidney Int 85 2014 579 589
43. J.S. Duffield Cellular and molecular mechanisms in kidney fibrosis J Clin Invest 124 2014 2299 2306
44. G. Ramesh, and W.B. Reeves TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity J Clin Invest 110 2002 835 842
45. L.L. Falke, S. Gholizadeh, R. Goldschmeding, and et al. Diverse origins of the myofibroblast-implications for kidney fibrosis Nat Rev Nephrol 11 2015 233 244
46. S.M. Weis, and D.A. Cheresh Pathophysiological consequences of VEGF-induced vascular permeability Nature 437 2005 497 504
47. K. Negishi, E. Noiri, R. Maeda, and et al. Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury Kidney Int 73 2008 1374 1384
48. I. Grgic, G. Campanholle, V. Bijol, and et al. Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis Kidney Int 82 2012 172 183
49. K. Hishikawa, T. Marumo, S. Miura, and et al. Musculin/MyoR is expressed in kidney side population cells and can regulate their function J Cell Biol 169 2005 921 928
50. M. Nishikawa, H. Nagatomi, M. Nishijima, and et al. Targeting superoxide dismutase to renal proximal tubule cells inhibits nephrotoxicity of cisplatin and increases the survival of cancer-bearing mice Cancer Lett 171 2001 133 138
51. J. Yamate, A. Ishida, K. Tsujino, and et al. Immunohistochemical study of rat renal interstitial fibrosis induced by repeated injection of cisplatin, with special reference to the kinetics of macrophages and myofibroblasts Toxicol Pathol 24 1996 199 206
52. E. Noiri, K. Doi, K. Negishi, and et al. Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury Am J Physiol Renal Physiol 296 2009 F669 F679
53. J.V. Bonventre Primary proximal tubule injury leads to epithelial cell cycle arrest, fibrosis, vascular rarefaction, and glomerulosclerosis Kidney Int Supplements 4 2014 39 44
54. F.T. Borges, S.A. Melo, B.C. Ozdemir, and et al. TGF-beta1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis J Am Soc Nephrol 24 2013 385 392
55. M. Mack, and M. Yanagita Origin of myofibroblasts and cellular events triggering fibrosis Kidney Int 87 2015 297 307
56. S. Hakroush, M.J. Moeller, F. Theilig, and et al. Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease Am J Pathol 175 2009 1883 1895
57. C. Schrimpf, and J.S. Duffield Mechanisms of fibrosis: the role of the pericyte Curr Opin Nephrol Hypertens 20 2011 297 305
58. T. Tanaka, K. Doi, R. Maeda-Mamiya, and et al. Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury Am J Pathol 174 2009 1203 1211
59. Y. Hamasaki, K. Doi, R. Maeda-Mamiya, and et al. A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1 Am J Physiol Renal Physiol 305 2013 F1796 F1803
60. M. Salmi, and S. Jalkanen A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans Science 257 1992 1407 1409
61. M. Salmi, G.G. Yegutkin, R. Lehvonen, and et al. A cell surface amine oxidase directly controls lymphocyte migration Immunity 14 2001 265 276
62. C.J. Weston, E.L. Shepherd, L.C. Claridge, and et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis J Clin Invest 125 2015 501 520
63. N. Mercier, M. Osborne-Pellegrin, K. El Hadri, and et al. Carotid arterial stiffness, elastic fibre network and vasoreactivity in semicarbazide-sensitive amine-oxidase null mouse Cardiovasc Res 72 2006 349 357
64. R. Kurkijarvi, D.H. Adams, R. Leino, and et al. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases J Immunol 161 1998 1549 1557
65. M.S. Lin, H.Y. Li, J.N. Wei, and et al. Serum vascular adhesion protein-1 is higher in subjects with early stages of chronic kidney disease Clin Biochem 41 2008 1362 1367
66. H.Y. Li, Y.D. Jiang, T.J. Chang, and et al. Serum vascular adhesion protein-1 predicts 10-year cardiovascular and cancer mortality in individuals with type 2 diabetes Diabetes 60 2011 993 999
67. K. Aalto, M. Maksimow, M. Juonala, and et al. Soluble vascular adhesion protein-1 correlates with cardiovascular risk factors and early atherosclerotic manifestations Arterioscler Thromb Vasc Biol 32 2012 523 532
68. F. Boomsma, A.H. van den Meiracker, S. Winkel, and et al. Circulating semicarbazide-sensitive amine oxidase is raised both in type I (insulin- dependent), in type II (non-insulin-dependent) diabetes mellitus and even in childhood type I diabetes at first clinical diagnosis Diabetologia 42 1999 233 237
69. H.Y. Li, J.N. Wei, M.S. Lin, and et al. Serum vascular adhesion protein-1 is increased in acute and chronic hyperglycemia Clin Chim Acta 404 2009 149 153
70. S. Jalkanen, and M. Salmi VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation Arterioscler Thromb Vasc Biol 28 2008 18 26
71. P.H. Yu, S. Wright, E.H. Fan, and et al. Physiological and pathological implications of semicarbazide-sensitive amine oxidase Biochim Biophys Acta 1647 2003 193 199
72. H.M. Bolt Experimental toxicology of formaldehyde J Cancer Res Clin Oncol 113 1987 305 309
73. H.D. Heck, M. Casanova, and T.B. Starr Formaldehyde toxicity-new understanding Crit Rev Toxicol 20 1990 397 426
74. S. Baba, Y. Watanabe, F. Gejyo, and et al. High-performance liquid chromatographic determination of serum aliphatic amines in chronic renal failure Clin Chim Acta 136 1984 49 56
75. P.H. Yu, and R.F. Dyck Impairment of methylamine clearance in uremic patients and its nephropathological implications Clin Nephrol 49 1998 299 302
76. J.S. Foot, T.T. Yow, H. Schilter, and et al. PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo. J Pharmacol Exp Ther 347 2013 365 374
77. A.M. O'Rourke, E.Y. Wang, A. Miller, and et al. Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity J Pharmacol Exp Ther 324 2008 867 875
78. G. Barrera Oxidative stress and lipid peroxidation products in cancer progression and therapy ISRN Oncol 2012 2012 137289
79. C. Casares, R. Ramirez-Camacho, A. Trinidad, and et al. Reactive oxygen species in apoptosis induced by cisplatin: review of physiopathological mechanisms in animal models Eur Arch Otorhinolaryngol 269 2012 2455 2459
80. X. Wang, K. Desai, J.T. Clausen, and et al. Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats Kidney Int 66 2004 2315 2321
81. D. Portilla, S. Li, K.K. Nagothu, and et al. Metabolomic study of cisplatin-induced nephrotoxicity Kidney Int 69 2006 2194 2204
82. M. Herman-Edelstein, P. Scherzer, A. Tobar, and et al. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy J Lipid Res 55 2014 561 572
83. H.M. Kang, S.H. Ahn, P. Choi, and et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development Nat Med 21 2015 37 46
84. D. Tampe, and M. Zeisberg Potential approaches to reverse or repair renal fibrosis Nat Rev Nephrol 10 2014 226 237
85. T. Yamamoto, E. Noiri, Y. Ono, and et al. Renal L-type fatty acid-binding protein in acute ischemic injury J Am Soc Nephrol 18 2007 2894 2902
86. P.S. Yuen, S.R. Dunn, T. Miyaji, and et al. A simplified method for HPLC determination of creatinine in mouse serum Am J Physiol Renal Physiol 286 2004 F1116 F1119
87. J.D. Conger, M.F. Schultz, F. Miller, and et al. Responses to hemorrhagic arterial pressure reduction in different ischemic renal failure models Kidney Int 46 1994 318 323
88. E. Noiri, T. Peresleni, F. Miller, and et al. In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia J Clin Invest 97 1996 2377 2383
89. S. Hara, K. Umeyama, T. Yokoo, and et al. Diffuse glomerular nodular lesions in diabetic pigs carrying a dominant-negative mutant hepatocyte nuclear factor 1-alpha, an inheritant diabetic gene in humans PLoS One 9 2014 e92219
90. C.D. Blackstock, Y. Higashi, S. Sukhanov, and et al. Insulin-like growth factor-1 increases synthesis of collagen type I via induction of the mRNA-binding protein LARP6 expression and binding to the 5' stem-loop of COL1a1 and COL1a2 mRNA J Biol Chem 289 2014 7264 7274
91. J. Hao, Y.J. Zhang, X. Lv, and et al. IFN-gamma induces lipogenesis in mouse mesangial cells via the JAK2/STAT1 pathway Am J Physiol Cell Physiol 304 2013 C760 C767
92. L.S. Lara, M. McCormack, L.C. Semprum-Prieto, and et al. AT1 receptor-mediated augmentation of angiotensinogen, oxidative stress, and inflammation in ANG II-salt hypertension Am J Physiol Renal Physiol 302 2012 F85 F94
93. T.C. Huang, S.M. Chen, Y.C. Li, and et al. Increased renal semicarbazide-sensitive amine oxidase activity and methylglyoxal levels in aristolochic acid-induced nephrotoxicity Life Sci 114 2014 4 11